These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35587447)

  • 1. JMM Profile:
    Bonis BM; Hunter RC
    J Med Microbiol; 2022 May; 71(5):. PubMed ID: 35587447
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
    Warner NC; Bartelt LA; Lachiewicz AM; Tompkins KM; Miller MB; Alby K; Jones MB; Carr AL; Alexander J; Gainey AB; Daniels R; Burch AK; Brown DE; Brownstein MJ; Cheema F; Linder KE; Shields RK; Longworth S; van Duin D
    Clin Infect Dis; 2021 Oct; 73(7):e1754-e1757. PubMed ID: 33313656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.
    Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M
    Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.
    Stobbelaar K; Van Hoorenbeeck K; Lequesne M; De Dooy J; Ho E; Vlieghe E; Ieven M; Verhulst S
    Am J Case Rep; 2016 Aug; 17():562-6. PubMed ID: 27498677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.
    Talbot NP; Flight WG
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The
    Pickrum AM; Riegert MO; Wells C; Brockman K; Frank DW
    Microbiol Spectr; 2022 Aug; 10(4):e0208322. PubMed ID: 35856670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.
    Llorca Otero L; Girón Moreno R; Buendía Moreno B; Valenzuela C; Guiu Martínez A; Alarcón Cavero T
    Enferm Infecc Microbiol Clin; 2016 Mar; 34(3):184-7. PubMed ID: 26139304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case of Phage Therapy against Pandrug-Resistant
    Lebeaux D; Merabishvili M; Caudron E; Lannoy D; Van Simaey L; Duyvejonck H; Guillemain R; Thumerelle C; Podglajen I; Compain F; Kassis N; Mainardi JL; Wittmann J; Rohde C; Pirnay JP; Dufour N; Vermeulen S; Gansemans Y; Van Nieuwerburgh F; Vaneechoutte M
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33466377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the
    Le Goff M; Vastel M; Lebrun R; Mansuelle P; Diarra A; Grandjean T; Triponney P; Imbert G; Gosset P; Dessein R; Garnier F; Durand E
    Front Cell Infect Microbiol; 2022; 12():859181. PubMed ID: 35782124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
    Bador J; Amoureux L; Blanc E; Neuwirth C
    Antimicrob Agents Chemother; 2013 Jan; 57(1):603-5. PubMed ID: 23089757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exoproducts of the Most Common
    Sahl C; Baumgarten M; Shannon O; Påhlman LI
    Microbiol Spectr; 2023 Aug; 11(4):e0019523. PubMed ID: 37284754
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.
    Pereira RH; Leão RS; Carvalho-Assef AP; Albano RM; Rodrigues ER; Firmida MC; Folescu TW; Plotkowski MC; Bernardo VG; Marques EA
    Epidemiol Infect; 2017 Feb; 145(3):600-606. PubMed ID: 27873565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duplex real-time PCR assay for the simultaneous detection of
    Price EP; Soler Arango V; Kidd TJ; Fraser TA; Nguyen TK; Bell SC; Sarovich DS
    Microb Genom; 2020 Jul; 6(7):. PubMed ID: 32667877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and variability of siderophore production in the
    Sorlin P; Brivet E; Jean-Pierre V; Aujoulat F; Besse A; Dupont C; Chiron R; Jumas-Bilak E; Menetrey Q; Marchandin H
    Microbiol Spectr; 2024 Mar; 12(3):e0295323. PubMed ID: 38315029
    [No Abstract]   [Full Text] [Related]  

  • 16. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.
    Pongchaikul P; Santanirand P; Antonyuk S; Winstanley C; Darby AC
    FEMS Microbiol Lett; 2020 Jul; 367(14):. PubMed ID: 32592387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes.
    Jakobsen TH; Hansen MA; Jensen PØ; Hansen L; Riber L; Cockburn A; Kolpen M; Rønne Hansen C; Ridderberg W; Eickhardt S; Hansen M; Kerpedjiev P; Alhede M; Qvortrup K; Burmølle M; Moser C; Kühl M; Ciofu O; Givskov M; Sørensen SJ; Høiby N; Bjarnsholt T
    PLoS One; 2013; 8(7):e68484. PubMed ID: 23894309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.
    Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850
    [No Abstract]   [Full Text] [Related]  

  • 19. Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.
    Magni A; Trancassini M; Varesi P; Iebba V; Curci A; Pecoraro C; Cimino G; Schippa S; Quattrucci S
    J Clin Microbiol; 2010 Apr; 48(4):1035-9. PubMed ID: 20107101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
    Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
    J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.